High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: Long-term results

M. G. Salerno, G. Ferrandina, S. Greggi, L. Pierelli, G. Menichella, G. Leone, G. Scambia, S. Mancuso

Research output: Contribution to journalArticlepeer-review


The aim of this study was to assess the long-term impact of high-dose chemotherapy (HDC) as consolidation in a large series (n = 55) of advanced chemosensitive ovarian cancer patients who were optimally cytoreduced at time of first surgery or at interval debulking surgery (IDS). HDC consisted of carboplatin (600 mg/m2 days 1 and 2), etoposide (450 mg/m2 days 1 and 2) and melphalan (50 mg/m2, days 3 and 4). The primary endpoint of the study was the assessment of time to progression (TTP) and overall survival (OS). In September 2000 the overall population had a median follow-up of 55 months (range 17-137) and a TTP of 35 months with a 5-year TTP rate of 35% (CI 95%: 21-49) whereas OS averaged 75 months with a 5-year OS of 59% (CI 95%: 45-73). In patients achieving optimal primary cytoreduction the median TTP was 44 months with a 5-year rate of 43% (CI 95%: 26-60). In the same series the 5-year OS rate was 62% (CI 95%: 45-79) (median OS = 75 months). In patients who were optimally cytoreduced at the time of IDS the median TTP was 25 months and the 5-year TTP rate was 22% (CI 95%: 3-41) and median OS was 46 months with a 5-year OS rate of 50% (CI 95%: 27-73). HDC with hematopoietic support could represent an effective approach for the treatment of advanced optimally cytoreduced ovarian cancer patients with chemosensitive disease. Patients who underwent IDS because of unresectable tumors at the time of first surgery had the greater survival benefit from HDC.

Original languageEnglish
Pages (from-to)1017-1025
Number of pages9
JournalBone Marrow Transplantation
Issue number10
Publication statusPublished - 2001


  • Ovarian cancer
  • Very high-dose chemotherapy

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: Long-term results'. Together they form a unique fingerprint.

Cite this